<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983407</url>
  </required_header>
  <id_info>
    <org_study_id>AVB500-PC-005</org_study_id>
    <nct_id>NCT04983407</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Pancreatic Adenocarcinoma</brief_title>
  <official_title>A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aravive, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aravive, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of&#xD;
      AVB-S6-500 in combination with nab-paclitaxel and gemcitabine in subjects with locally&#xD;
      advanced, recurrent, or metastatic pancreatic adenocarcinoma as first line therapy. The phase&#xD;
      1b portion of the study is open label and patients will receive AVB-S6-500, nab-paclitaxel,&#xD;
      and gemcitabine. The Phase 2 portion of the study is randomized, 2-arm, open-label study to&#xD;
      compare efficacy and tolerability of AVB-S6-500, nab-paclitaxel, and gemcitabine versus&#xD;
      nab-paclitaxel and gemcitabine as first line therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by the number of patients with AEs in Phase 1b portion of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of AVB-S6-500 in combination with nab-paclitaxel and gemcitabine in Phase 1b portion of the study</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by Objective Response Rate (ORR): Proportion of subjects who have a partial or complete response to therapy relative to baseline in Phase 1b portion of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity of AVB-S6-500 in combination with nab-paclitaxel and gemcitabine in Phase 2 portion of the study</measure>
    <time_frame>30 months</time_frame>
    <description>Measured by progression free survival (PFS) in patients receiving AVB-S6-500, nab-paclitaxel, and gemcitabine versus patients receiving nab-paclitaxel, and gemcitabine alone in Phase 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC</measure>
    <time_frame>30 months</time_frame>
    <description>Area under the AVB-S6-500 concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>30 months</time_frame>
    <description>Maximum observed AVB-S6-500 concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Tmax</measure>
    <time_frame>30 months</time_frame>
    <description>Time of maximum observed AVB-S6-500 concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: t1/2</measure>
    <time_frame>30 months</time_frame>
    <description>Apparent terminal half-life of AVB-S6-500.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic marker assessment</measure>
    <time_frame>30 months</time_frame>
    <description>Change from the baseline in GAS6 serum levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA) titers</measure>
    <time_frame>30 months</time_frame>
    <description>Change from baseline in ADA titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>30 months</time_frame>
    <description>Proportion of subjects who have a complete or partial response to therapy or maintain stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>30 months</time_frame>
    <description>Measured from the date of partial or complete response to therapy until the cancer progresses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>60 months</time_frame>
    <description>Time following the treatment until death.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Phase 1b: AVB-S6-500+ nab-paclitaxel and gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: AVB-S6-500+ nab-paclitaxel and gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: nab-paclitaxel and gemcitabine alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVB-S6-500</intervention_name>
    <description>AVB-S6-500 is experimental drug</description>
    <arm_group_label>Phase 1b: AVB-S6-500+ nab-paclitaxel and gemcitabine</arm_group_label>
    <arm_group_label>Phase 2: AVB-S6-500+ nab-paclitaxel and gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab paclitaxel</intervention_name>
    <description>Nab paclitaxel is active comparator</description>
    <arm_group_label>Phase 1b: AVB-S6-500+ nab-paclitaxel and gemcitabine</arm_group_label>
    <arm_group_label>Phase 2: AVB-S6-500+ nab-paclitaxel and gemcitabine</arm_group_label>
    <arm_group_label>Phase 2: nab-paclitaxel and gemcitabine alone</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is active comparator</description>
    <arm_group_label>Phase 1b: AVB-S6-500+ nab-paclitaxel and gemcitabine</arm_group_label>
    <arm_group_label>Phase 2: AVB-S6-500+ nab-paclitaxel and gemcitabine</arm_group_label>
    <arm_group_label>Phase 2: nab-paclitaxel and gemcitabine alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Histologically or cytologically confirmed pancreatic adenocarcinoma. Must have locally&#xD;
             advanced, recurrent, or metastatic disease ineligible for curative intent treatment(s)&#xD;
             and eligible for first line systemic treatment.&#xD;
&#xD;
          -  Must have radiologic imaging with a computed tomography (CT) scan or magnetic&#xD;
             resonance imaging (MRI) within 22 days of study entry&#xD;
&#xD;
          -  Must have at least one measurable lesion according to RECIST 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Adequate gastrointestinal (GI), bone marrow, liver and kidney function&#xD;
&#xD;
          -  Life expectancy minimum of &gt; 12 weeks&#xD;
&#xD;
          -  Adequate recovery from surgery to Grade 1 or baseline with at least 28 days from time&#xD;
             of major surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received last dose of chemotherapy (neoadjuvant or adjuvant), surgery, or radiation&#xD;
             treatment with curative intent within 6 months prior to study entry&#xD;
&#xD;
          -  Islet-cell neoplasms&#xD;
&#xD;
          -  Prior malignancy within the past 3 years except adequately treated basal or squamous&#xD;
             cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate,&#xD;
             cervix or breast&#xD;
&#xD;
          -  Symptomatic uncontrolled central nervous system (CNS) metastasis or brain metastases&#xD;
             unless adequately treated and controlled&#xD;
&#xD;
          -  Evidence of clinically significant third spacing (e.g. pleural effusion, ascites,&#xD;
             anasarca, etc.) within 28 days prior to study entry&#xD;
&#xD;
          -  Serious active infection requiring IV antibiotics and/or hospitalization at study&#xD;
             entry&#xD;
&#xD;
          -  Active human immune deficiency (HIV) syndrome, hepatitis B, hepatitis C, or other&#xD;
             active viral illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Franke</last_name>
    <role>Study Director</role>
    <affiliation>Aravive, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aravive Clinical Trials</last_name>
    <phone>936-355-1910</phone>
    <email>clinicaltrials@aravive.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scripps MD Anderson Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Darren Sigal, MD</last_name>
      <phone>858-554-8788</phone>
      <email>Sigal.Darren@scrippshealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Health</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Yonemoto</last_name>
      <phone>310-633-8400</phone>
      <email>Lyonemoto@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital / Lynn Cancer Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie Godbout</last_name>
      <phone>561-955-4539</phone>
      <email>sgodbout@baptisthealth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffit Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Ponto</last_name>
      <phone>813-745-7658</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine - University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cancer AnswerLine</last_name>
      <phone>800-865-1125</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roswell Park Clinical Trials Information Line</last_name>
      <phone>800-767-9355</phone>
      <email>askroswell@roswellpark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perlmutter Cancer Center at NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pamela Baga</last_name>
      <phone>212-731-6221</phone>
      <email>Pamela.Baga@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center (DUMC)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DUMC Protocol Office</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffany Schaafsma, RN</last_name>
      <phone>216-445-1510</phone>
      <email>AAFT@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Knight Clinical Trials Information Line</last_name>
      <phone>503-494-1080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Hoffer</last_name>
      <phone>215-349-8913</phone>
      <email>khoffer@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University / Sidney Kimmel Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>215-955-1661</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Efrat Dotan, MD</last_name>
      <phone>888-369-2427</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHN Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>(412) 330-6151</last_name>
      <email>clinicaltrials@ahn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carrie Friedman</last_name>
      <phone>703-636-1473</phone>
      <email>vcsclinicaltrials@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MCW Cancer Center Clinical Trials Office</last_name>
      <phone>414-805-8900</phone>
      <email>cccto@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced</keyword>
  <keyword>recurrent</keyword>
  <keyword>metastatic</keyword>
  <keyword>pancreatic</keyword>
  <keyword>exocrine</keyword>
  <keyword>pancreas</keyword>
  <keyword>adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

